Advancing early cancer screening and detection.
Identifying cancer and other diseases with high sensitivity, specificity, and accuracy.
Anpac Bio uses proprietary, multi-level multi-parameter screening algorithms to identify cancer.
Detects the risks of 26 different types of cancer—often identifying cancer at its early stages: Covering 80% of cancer incidences in China from 2013 to 2018
121 issued patents granted to date around its Cancer Differentiation Analysis (“CDA”) technology.
Significant cost advantages compared to other screening technologies
Anpac Bio scientists have published and presented verified research studies at the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit on Biomedical Sciences, among others.
Shared philosophies, cultural alignment, and an open exchange of ideas unifies our efforts as we continue to pioneer the “liquid biopsy” market, proving theory with evidence.
CDA technology is called “game-changing” in Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.
Read the full article